ERBB2 and breast cancer: One study described how neratinib, a pan-HER tyrosine kinase inhibitor, induced senescence in HER2+ breast cancer cells (AU565 cell line) by increasing mitochondrial reactive oxygen species (ROS) and DNA damage.